The pharmaceutical company, Biogen, announced this week that it will stop developing and marketing the Alzheimer’s drug aducanumab (commercially known as Aduhelm).   Aducanumab is designed to target and clear amyloid, one of the hallmark proteins that builds up in the brains of people with Alzheimer’s, at an early stage of the disease. This is similar…

The post Development and sale of Alzheimer’s drug, aducanumab, ceased appeared first on Alzheimer's Research UK.